Sensitive immunodetection of radiotoxicity after iodine-131 therapy for thyroid cancer using γ-H2AX foci of DNA damage in lymphocytes

Annals of Nuclear Medicine

Volumn 27, Issue 3, 2013, Pages 233-238

  Doai, Mariko ^a   Watanabe, Naoto ^a   Takahashi, Tomoko ^a   Taniguchi, Mitsuru ^a   Tonami, Hisao ^a   Iwabuchi, Kuniyoshi ^a   Kayano, Daiki ^b   Fukuoka, Makoto ^b   Kinuya, Seigo ^b  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

H2AX; DNA damage; Radioiodine 131 therapy; Radiotoxicity

Indexed keywords

HISTONE H2AX; IODINE 131;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIATED THYROID CANCER; DNA DAMAGE; FEMALE; HUMAN; HUMAN CELL; IMMUNODETECTION; IN VITRO STUDY; IONIZING RADIATION; LYMPHOCYTE; MALE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIOTOXICITY; X IRRADIATION;

ADULT; DNA DAMAGE; FEMALE; HISTONES; HUMANS; IODINE RADIOISOTOPES; LYMPHOCYTES; MALE; MIDDLE AGED; RADIATION DOSAGE; THYROID NEOPLASMS;

EID: 84880698245     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-012-0678-0     Document Type: Article

References (22)

1. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941-59.
2. Hurley JR, Becker DV. Treatment of thyroid carcinoma with radioiodine. In: Gottshalk A, Hoffer PB, Potchen EJ, editors. Diagnostic nuclear medicine. 2nd ed. Baltimore: Williams & Wilkins; 1988. p. 792-814.
3. Hurley JR, Becker DV. The use of radioiodine in the management of thyroid cancer. In: Freeman LM, Weissman HS, editors. Nuclear medicine annual. New York: Raven Press; 1983. p. 329-84.
4. Chow SM. Side effects of high-dose radioactive iodine for ablation or treatment of differentiated thyroid carcinoma. J HK Coll Radiol. 2005;8:127-35.
5. Leeper R. Controversies in the treatment of thyroid cancer. The New York Memorial Hospital approach. Thyroid Today 1982;5:1-6.
6. Maxon HR, Smith HS. Radioiodine-131 in the treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990;19:685-718.
7. M'Kacher R, Legal JD, Schlumberger M, Vosin P, Aubert B, Gaillard N, et al. Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma. J Nucl Med. 1996;37:1860-4.
8. Monsieurs MA, Thierens HM, van de Wiele C, Vral AM, Meirlaen IA, de Winter HA, et al. Estimation of risk based on biological dosimetry for patients treated with radioiodine. Nucl Med Commun. 1999;20:911-7.
9. 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. J Nucl Med. 2004;45:608-11.
10. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273:5858-68.
11. Rogakou EP, Boon C, Redon C, Bonner WM. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J Cell Biol. 1999;146:905-15.
12. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem. 2001;276:42462-7.
13. Rothkamm K, Löbrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low X-ray doses. PNAS. 2003;100:5057-506.
14. Rothkamm K, Balroop S, Shekhdar J, Fernie P, Goh V. Leukocyte DNA damage after multi-detector row CT: a quantitative biomarker of low-level radiation exposure. Radiology. 2007;242:244-51.
15. Kuefner MA, Grudzenski S, Hamann J, Achenbach S, Lell M, Anders K, et al. Effect of CT scan protocols on X-ray-Induced DNA double-strand breaks in blood lymphocyte of patients undergoing coronary CT angiography. Eur Radiol. 2010;20:2917-24.
16. Beels L, Bacher K, de Wolf D, Werbrouck J, Thierens H. γ-H2AX foci as a biomarker for patient X-ray exposure in pediatric cardiac catheterization are we underestimating radiation risks? Circulation. 2009;10:1903-9.
17. Horn S, Barnard S, Rothkamm K. Gamma-H2AX-based dose estimation for whole and partial body radiation exposure. PLoS One. 2011;6(9):e25113.
18. Sak A, Grehl S, Erichsen P, Engelhard M, Graraß, Levegrün S, et al. γ-H2AX foci formation in peripheral blood lymphocytes of tumor patients after focal radiotherapy to different sites of the body: dependence on the dose-distribution, irradiated site and time from start of treatment. Int J Radiat Biol. 2007;83:639-52.
19. Lassmann M, Hänscheid H, Gassen D, Biko J, Meineke V, Reiners C, et al. In vivo formation of γ-H2AX and 53BP1 DNA repair foci in blood cells after radioiodine therapy of differentiated thyroid cancer. J Nucl Med. 2010;51:1318-25.
20. Thomas JP, Lautermann J, Liedert B, Seiler F, Thomale J. High accumulation of platinum-DNA adducts in strial marginal cells of the cochlea is an early event in cisplatin but not carboplatin ototoxicity. Mol Phamacol. 2006;70:23-9.
21. Collis SJ, Schwaninger JM, Natanbi AJ, Keller TW, Nelson WG, Dillehay LE, et al. Evasion of early cellular response mechanisms following low level radiation induced DNA damage. J Biol Chem. 2004;279:49624-32.
22. Hall EJ, Giaccia AJ. Radiobiology for the radiologist: molecular mechanism of DNA and chromosome damage and repair. 7th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Willkins; 2012. p. 12-34.